* Unclear when Humira biosimilar would start sales (Adds background on Samsung Bioepis)
SEOUL, July 18 Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group, said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira.
02:10 Attorney General's office announces settlement with drug manufacturer9
09:43 ThyssenKrupp secrets stolen in 'massive' cyber attack this year24
18:30 White Sox trade Chris Sale to Red Sox for Yoan Moncada, three others14
16:38 Swift Energy completes $40 million sale of Louisiana asset13